Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy

Genotypic Evaluation of Chronic Exudative Macular Degeneration Despite Monthly Anti-Vascular Endothelial Growth Factor (VEGF) Therapy

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01310686

Enrollment

Registered

2011-03-08

Start date

2011-04-30

Completion date

2019-06-30

Last updated

2018-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wet AMD

Keywords

wet AMD anti-VEGF, Genetic analysis of patients with Wet AMD who have not responded fully to anti-VEGF treatments

Brief summary

To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Ability to provide written informed consent for participation in this study * Subjects diagnoses of neovascular AMD who are on a monthly anti-VEGF regimen (have had \>10 or more ranibizumab and/or bevacizumab injections within the last year) and who still have intra-retinal or subretinal fluid as confirmed by the Investigator

Exclusion criteria

* Subjects with a Pigment Epithelial Detachment Exclusively * Subjects with Serous Pigment Epithelial Detachments * Subjects with history of the following: idiopathic polypoidal choroidal vasculopathy * pathologic degenerative myopia * central serous chorioretinopathy * familial drusen * adult onset foveal pattern dystrophy

Design outcomes

Primary

Measure	Time frame
Genetic analysis of patients with chronic wet age-related macular degeneration despite continuous anti-VEGF treatment	This is a one time only blood draw.

Secondary

Measure	Time frame
To evaluate demographic and clinical characteristics in patients treated with anti-VEGF therapy who fail to respond completely.	This is a one time only blood draw and assessment of clinical characteristics.

Countries

United States

Outcome results